Profile data is unavailable for this security.
About the company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
- Revenue in USD (TTM)151.93m
- Net income in USD23.40m
- Incorporated2012
- Employees38.00
- LocationAtara Biotherapeutics Inc1280 Rancho Conejo BlvdTHOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 623-4211
- Fax+1 (302) 636-5454
- Websitehttps://www.atarabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantern Pharma Inc | 0.00 | -18.92m | 32.55m | 24.00 | -- | 3.35 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| NextCure Inc | 0.00 | -58.01m | 32.83m | 43.00 | -- | 1.39 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 34.01m | 46.00 | -- | 0.5119 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 34.10m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Galecto Inc | 0.00 | -15.84m | 34.33m | 5.00 | -- | 4.28 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 34.83m | 38.00 | 2.20 | -- | 1.31 | 0.2292 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 34.84m | 39.00 | -- | 1.15 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 35.41m | 52.00 | -- | 9.61 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 35.46m | 10.00 | -- | 1.27 | -- | 8.81 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.56m | 37.00 | -- | 2.58 | -- | 395.15 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.57m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 36.66m | 64.00 | -- | 3.17 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 37.08m | 20.00 | -- | 1.85 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 37.36m | 24.00 | -- | 3.60 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Atara Biotherapeutics Inc's reporting currency: US Dollar USD
22.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Sep 2025 | 573.18k | 7.95% |
| Redmile Group LLCas of 12 Nov 2025 | 441.70k | 6.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 190.86k | 2.65% |
| Marshall Wace LLPas of 30 Sep 2025 | 115.80k | 1.61% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 64.42k | 0.89% |
| Mackenzie Financial Corp.as of 30 Sep 2025 | 63.82k | 0.89% |
| Geode Capital Management LLCas of 30 Sep 2025 | 60.53k | 0.84% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 56.42k | 0.78% |
| Staley Capital Advisers, Inc.as of 31 Dec 2025 | 50.00k | 0.69% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 35.82k | 0.50% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
